{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.26","upperLimit":"19.75","value":"13.11"},{"groupId":"OG001","lowerLimit":"5.39","upperLimit":"18.73","value":"10.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Duration of objective response is defined as the time from study start date to response, CR or partial response, PR) to the date of the first documented tumor progression as determined by the investigator (per RECIST 1.1 criteria or clinical) or death due to any cause, whichever occurred first. For participants who neither progress nor die, the duration of objective response were censored at the same time they were censored for the primary definition. CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR=At least a 30% decrease in the sum of diameters of target lesions, the baseline sum diameters used as reference. Based on Kaplan-Meier Estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with a response; any participants that were randomized to any treatment group in the study and that had a response.","reportingStatus":"POSTED","timeFrame":"From randomization to date of disease progression or death or censoring if no progression or death occurred (approximately 105 months)","title":"Investigator-assessed Duration of Objective Response","type":"SECONDARY","unitOfMeasure":"months"}